Is This $5 Billion Biotech IPO a Buy?
Single-cell analysis took a little while to arrive, but the analytical approach is finally proving its worth in biology labs across the globe. It's also starting to power considerable growth for companies well-positioned to capture the opportunity. That includes 10X Genomics (NASDAQ: TXG), which recently completed a successful initial public offering (IPO).
The company has enjoyed triple-digit year-over-year growth and strong investor appetite for IPOs has handed the laboratory hardware business a $5 billion market valuation. It offers a slick lineup of products to customers and expects to continue growing at a healthy clip. Despite the relatively great start to life on the public market, the company faces serious patent-infringement suits from Bio-Rad Laboratories (NYSE: BIO). Is 10X Genomics a buy?
Image source: Getty Images.
Source Fool.com
